Advancing ADC Development: Overcoming Preclinical Challenges With Labcorp Discovery Oncology

By Gunisha Arora, Ph.D., Medical and Scientific Writer, Scientific Development

Antibody-drug conjugates (ADCs) have reshaped cancer treatment by combining the precision of targeted therapies with the potency of chemotherapy, offering new hope for patients with difficult-to-treat cancers such as breast, lung, and hematologic malignancies. Yet, despite their promise, ADC development faces significant hurdles. Preclinical studies often suffer from inconsistent designs, long timelines, and high costs, creating a translational gap where encouraging preclinical data fails to replicate in clinical trials.

Labcorp helps bridge this gap by providing end-to-end preclinical services — from target identification and antibody characterization to in vitro and in vivo efficacy studies and IND-enabling toxicology packages. With deep scientific expertise and robust study design, we accelerate ADC development and increase the likelihood of successful clinical translation.